By Thomas Winstanley, Edibles.com
The hemp-derived CBD market has long occupied a contradictory position: federally legal, widely available, and integrated into everyday wellness routines, yet lacking a coherent regulatory framework. The Food and Drug Administration's (FDA) recent enforcement discretion for certain CBD products is a meaningful step—but one that underscores how incomplete and fragile the current system remains.
FDA's move signals it will not enforce certain provisions of the Federal Food, Drug and Cosmetic Act against qualifying orally administered CBD products, effectively adopting a supplement-style approach with guardrails around safety, labeling, and marketing. This is the first time in decades that cannabinoids are being discussed in terms echoing the Dietary Supplement Health and Education Act (DSHEA) of 1994—suggesting a viable lane aligned with how consumers engage with vitamins and nutraceuticals.
But the agency's position applies only within a narrow, physician-directed, Medicare-related framework. It does not establish CBD as Generally Recognized As Safe (GRAS), does not constitute full regulatory approval, and offers no durable protections for the broader market spanning retail, e-commerce, and direct-to-consumer platforms where millions of Americans already access these products.
Since the 2018 Farm Bill, hemp-derived products have grown into a multi-billion-dollar sector. Consumers use them for sleep support, stress management, and recovery. Responsible operators have invested in testing, labeling, and compliance, yet compete alongside bad actors exploiting regulatory gray areas amid a state-by-state patchwork of inconsistent standards.
Recent legislative developments add uncertainty: the narrowing of the federal hemp definition under the latest appropriations framework creates new ambiguity around product eligibility for cannabinoids outside traditional interpretations. Without clear federal standards, demand will not disappear—it will shift toward unregulated or imported products lacking safety oversight, while dismantling a domestic supply chain that has reached meaningful scale.
FDA's action signals executive-branch openness to integrating cannabinoids into established regulatory systems, and its emphasis on contamination-free products, responsible marketing, and clear labeling reflects baseline expectations the entire industry should meet. But selective enforcement is not regulation; it provides temporary flexibility, not lasting certainty.
“These products have the potential to reshape how Americans approach wellness by offering accessible, plant-based alternatives that complement traditional care, but realizing that potential will require more than enforcement discretion,” writes Thomas Winstanley, executive vice president and general manager of Edibles.com®.
Only Congress can establish the consistent federal standards—covering manufacturing, labeling, distribution, and access—this market requires.
Thomas Winstanley is the executive vice president and general manager of Edibles.com®, an innovative and trustworthy marketplace of high-quality THC products that offers convenient delivery direct to the consumer.
Photo courtesy of Kimzy Nanney.
